Improvement of renal function after transcatheter aortic valve replacement in patients with chronic kidney disease

About the Authors:

Michel V. Lemes da Silva

Roles Conceptualization, Formal analysis, Methodology, Project administration, Visualization, Writing – original draft, Writing – review & editing

Affiliations Department of Cardiology, Hospital Israelita Albert Einstein (Albert Einstein Hospital), Sao Paulo, Brazil, Department of Cardiology, Heart Institute (InCor), Clinical Hospital, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil

ORCID logo https://orcid.org/0000-0003-4257-4283

Antonio C. B. Nunes Filho

Roles Conceptualization, Formal analysis, Methodology, Project administration, Supervision, Visualization, Writing – original draft, Writing – review & editing

* E-mail: [email protected]

Affiliation: Department of Cardiology, Hospital Israelita Albert Einstein (Albert Einstein Hospital), Sao Paulo, Brazil

Vitor E. E. Rosa

Roles Conceptualization, Formal analysis, Methodology, Supervision, Writing – original draft, Writing – review & editing

Affiliations Department of Cardiology, Hospital Israelita Albert Einstein (Albert Einstein Hospital), Sao Paulo, Brazil, Department of Cardiology, Heart Institute (InCor), Clinical Hospital, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil

ORCID logo https://orcid.org/0000-0001-6521-2870

Adriano Caixeta

Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Project administration, Resources, Validation, Visualization, Writing – original draft, Writing – review & editing

Affiliation: Department of Cardiology, Hospital Israelita Albert Einstein (Albert Einstein Hospital), Sao Paulo, Brazil

ORCID logo https://orcid.org/0000-0002-6287-5414

Pedro A. Lemos Neto

Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Resources, Validation, Writing – original draft, Writing – review & editing

Affiliation: Department of Cardiology, Hospital Israelita Albert Einstein (Albert Einstein Hospital), Sao Paulo, Brazil

Henrique B. Ribeiro

Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Validation, Visualization, Writing – original draft

Affiliation: Department of Cardiology, Heart Institute (InCor), Clinical Hospital, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil

Breno O. Almeida

Roles Conceptualization, Data curation, Funding acquisition, Investigation, Project administration, Validation, Writing – original draft, Writing – review & editing

Affiliation: Department of Cardiology, Hospital Israelita Albert Einstein (Albert Einstein Hospital), Sao Paulo, Brazil

José Mariani Jr

Roles Conceptualization, Data curation, Funding acquisition, Investigation, Project administration, Resources, Validation, Visualization, Writing – original draft, Writing – review & editing

Affiliations Department of Cardiology, Hospital Israelita Albert Einstein (Albert Einstein Hospital), Sao Paulo, Brazil, Department of Cardiology, Heart Institute (InCor), Clinical Hospital, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil

Carlos M. Campos

Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Resources, Validation, Visualization, Writing – original draft, Writing – review & editing

Affiliations Department of Cardiology, Heart Institute (InCor), Clinical Hospital, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil, Department of Cardiology, Instituto Prevent Senior, Sao Paulo, Brazil

Alexandre A. C. Abizaid

Roles Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Validation, Visualization, Writing – original draft, Writing – review & editing

Affiliation: Department of Cardiology, Heart Institute (InCor), Clinical Hospital, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil

José A. Mangione

Roles Data curation, Funding acquisition, Investigation, Project administration, Resources, Visualization, Writing – original draft, Writing – review & editing

Affiliation: Department of Interventional Cardiology, Hospital Beneficiência Portuguesa, Sao Paulo, Brazil

Roney O. Sampaio

Roles Conceptualization, Formal analysis, Methodology, Validation, Visualization, Writing – original draft, Writing – review & editing

Affiliation: Department of Cardiology, Heart Institute (InCor), Clinical Hospital, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil

Paulo Caramori

Roles Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Resources, Validation, Visualization, Writing – original draft, Writing – review & editing

Affiliation: Department of Interventional Cardiology, Hospital São Lucas – PUCRS, Porto Alegre, Brazil

Rogério Sarmento-Leite

Roles Conceptualization, Data curation, Investigation, Methodology, Resources, Validation, Visualization, Writing – original draft, Writing – review & editing

Affiliation: Department of Interventional Cardiology, Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, Brazil

ORCID logo https://orcid.org/0000-0002-9674-8528

Flávio Tarasoutchi

Roles Conceptualization, Formal analysis, Validation, Visualization, Writing – original draft, Writing – review & editing

Affiliations Department of Cardiology, Hospital Israelita Albert Einstein (Albert Einstein Hospital), Sao Paulo, Brazil, Department of Cardiology, Heart Institute (InCor), Clinical Hospital, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil

Marcelo Franken

Roles Conceptualization, Formal analysis, Validation, Visualization, Writing – original draft, Writing – review & editing

Affiliation: Department of Cardiology, Hospital Israelita Albert Einstein (Albert Einstein Hospital), Sao Paulo, Brazil

Fábio S. de Brito Jr

Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing

Affiliation: Department of Cardiology, Heart Institute (InCor), Clinical Hospital, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil

Introduction

Transcatheter aortic valve replacement (TAVR) is a well-established treatment for patients who cannot undergo surgery and those with intermediate to high surgical risk with symptomatic severe aortic stenosis [1–6]. More recently, TAVR indications have also been expanded for patients at low surgical risk, as well as for dysfunctional bioprosthesis [7, 8].

Among the patients currently undergoing TAVR, a high prevalence of non-cardiac comorbidities are frequently observed, including chronic kidney disease (CKD) that ranged from 52% to 72% in prior studies [9–11]. Moreover, renal function impairment at baseline also denotes worse clinical outcomes following TAVR, including higher mortality rates [10–14], particularly when acute kidney injury (AKI) after TAVR ensues [9, 15–17]. Of note, some patients may also experience renal function improvement after TAVR, regardless of the baseline renal condition, and also despite the various procedural factors that could jeopardize renal function such as hypotension during rapid pacing, use of iodinated contrast media, bleeding and athero-emboli. Yet, such adverse effects may be mitigated by the beneficial effects after the AS relief leading to improvement in cardiac output and better renal perfusion [9, 15, 16].

However, there is divergence in recent studies about the effects of the improvement in renal function after TAVR regarding better outcomes, and its real role still needs more investigation [9, 16].

This study aims to determine the predictors and prognosis of renal function improvement after TAVR using data from the Brazilian TAVR Registry.

Methods

Study population

From January 2008 to January 2015, 819 consecutive patients with symptomatic severe AS underwent TAVR and were included in the Brazilian TAVR Registry [18], which is a non-randomized prospective registry, including 22 Brazilian centers. Patients with baseline impaired renal function, defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2, were selected. eGFR was calculated using Chronic Kidney Disease Epidemiology formula (CKD-EPI) [19], expressed by GFR = 141 * min(Scr/κ,1)α * max(Scr/κ, 1)-1.209 * 0.993Age * 1.018 [if female] * 1.159 [if black], which Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. Also, 25 patients who died within the first 24 hours and 60 patients with missing data (4 patients without baseline eGFR, 55 patients without eGFR at discharge and 1 patient without eGFR at both moments) were excluded, remaining 577 patients who were included in the study (Fig 1). The study protocol was conducted in accordance with the Declaration of Helsinki and was approved by each institution’s ethics committee under protocol number 05676012.4.1001.00701, and all participants had provided informed consent. The follow-up was performed by phone calls at 1 month, 1 year and then annually.

[Figure omitted. See PDF.]

Fig 1. Study flowchart.

Selection of the study population. Abbreviations: AS indicates aortic stenosis; eGFR, estimated glomerular filtration rate; TAVR, transcatheter aortic valve replacement.

https://doi.org/10.1371/journal.pone.0251066.g001

Procedure

Patients with symptomatic severe AS (aortic valve area < 1.0cm2 and mean aortic valve gradient of ≥ 40 mmHg or peak aortic jet velocity of ≥ 4.0 m/s) were submitted to TAVR with self-expandable CoreValve prosthesis (Medtronic, Minneapolis, MN, USA), balloon-expandable Sapien XT prosthesis (Edwards Lifesciences, Irvine, CA, USA) or balloon-expandable Inovare prosthesis (Braile Biomédica, São José do Rio Preto, SP, Brazil). TAVR procedures were performed according to standard techniques. Aspirin (100 mg/day) and clopidogrel (300 mg loading dose and 75 mg/day) were administered to patients for at least 1 month. The preferable access was the transfemoral approach. When it was not feasible, transapical or transarterial approaches (transubclavian, direct transaortic, transapical or transcarotid) were used according to the preference of the Heart Team. Clinical, procedural and echocardiographic data were prospectively gathered into a pre-set TAVR database. Outcomes were defined according to the Valve Academic Research Consortium 2 (VARC-2) [20]. All outcomes and adverse events were adjudicated by an independent committee.

Group definition

Serum creatinine was collected at baseline and daily after the procedure until discharge. The first creatinine (baseline) was collected on the day or the day before TAVR procedure. The second creatinine used to calculate variation on renal function was at discharge. The median length of stay was 7 days (1–368) and the mean hospitalization period was 13 days. The CKD-EPI formula was used to calculate the eGFR at baseline and at discharge after TAVR procedure. Patients were categorized according to renal function variation after TAVR: increase >10% in eGFR were classified as TAVR induced renal function improvement (TIRFI); decrease > 10% in eGFR were classified as AKI; and stable renal function (neither criteria) [9, 15].

Statistical analysis

Continuous variables were reported as mean ± standard deviation, and the comparison between the 3 groups was performed using the ANOVA test, except for contrast media volume which Kruskal-Wallis test was used. Post-hoc analysis was performed using Tukey’s test. Categorical variables were reported as frequencies and percentages, and were compared using the Pearson chi-square test. Cox proportional hazards models were used to test the impact of TIRFI and AKI on all-cause death and cardiovascular mortality, and the models were adjusted for age, male sex, New York Heart Association functional class III/IV, diabetes, hypertension, chronic obstructive lung disease, pulmonary hypertension, coronary artery disease, peripheral vascular disease, previous coronary artery bypass grafting, STS score, baseline eGFR, use of diuretics, Angiotensin-converting enzyme inhibitors or Angiotensin II receptor blockers, beta-blockers, statin, left ventricular ejection fraction, aortic valve area, mean aortic valve gradient, contrast media volume, procedural access (except transfemoral), Inovare prosthesis, AKI and TIRFI, myocardial infarction, stroke/transient ischemic attack, major or life-threatening bleeding, major vascular complication, new left bundle branch block, atrioventricular block, valve malpositioning and new pacemaker. Kaplan-Meier survival curves were created comparing TIRFI, stable renal function and AKI groups and the outcomes were compared using a log-rank test. A stepwise logistic regression analysis including all variables with a P value < 0.2 in the univariate analysis was used to identify the predictors of TIRFI and AKI after the procedure until discharge. The models were adjusted for age, male sex, New York Heart Association functional class III/IV, diabetes, hypertension, chronic obstructive lung disease, pulmonary hypertension, coronary artery disease, peripheral vascular disease, previous coronary artery bypass grafting, STS score, baseline eGFR, use of diuretics, Angiotensin-converting enzyme inhibitors or Angiotensin II receptor blockers, beta-blockers, statin, left ventricular ejection fraction, aortic valve area, mean aortic valve gradient, contrast media volume, procedural access (except transfemoral), Inovare prosthesis. All statistical tests were 2-sided, and the criteria for statistical significance was P < 0.05. All statistical analyses were performed using SPSS statistical software version 20.0 (IBM, Armonk, New York, USA).

Results

Baseline clinical characteristics

Baseline characteristics of the study population are presented in Table 1. A total of 577 (70%) patients had CKD and were the population of the present study. The overall median length of stay was 7 days (1–368) and the mean hospitalization period was 13 days. After TAVR, 197 (34.1%) patients had TIRFI, 177 (30.7%) maintained stable renal function and 203 (35.2%) had AKI. The overall mean age among CKD patients was 81.3 ± 6.8 years, 56.2% were male, 31.7% had diabetes, 74.5% had hypertension and the mean baseline eGFR was 39.1 ± 12.2 ml/min/1.73m2. The mean STS score was 10.6 ± 7.9% and the preferable access site was transfemoral (93.4%). Comparing baseline characteristics between the 3 groups, the mean eGFR was 37.3 ± 12.5 ml/min/1.73m2 in the TIRFI group, 39.6 ± 11.7 ml/min/1.73m2 in the stable renal function group and 40.2 ± 12.3 ml/min/1.73m2 in the AKI group, with significant statistical difference between the 3 groups (P = 0.043). This difference was related to TIRFI and AKI groups (post-hoc analysis, P = 0.044). Also, hypertension was present among 75.6% patients in TIRFI group, 66.1% in stable renal function group and 80.8% in AKI group, with significant difference between the 3 groups (P = 0.004). This difference was related to stable renal function and AKI groups (post-hoc analysis, P = 0.003). There was no difference related to contrast media volume and other baseline clinical, echocardiographic and procedural characteristics between the 3 groups. In order to evaluate the impact of the extended period of enrollment, we divided our study population into tertiles according to the year they underwent TAVR: 100 (17.3%) patients were submitted to TAVR from 2008 to 2010 (T1), 352 (61.0%) patients from 2011 to 2013 (T2), and 125 (21.7%) from 2014 to 2015 (T3), with no statistical differences between the 3 tertiles (p = 0.15).

[Figure omitted. See PDF.]

Table 1. Baseline and procedural characteristics of the study population.

https://doi.org/10.1371/journal.pone.0251066.t001

Procedural and clinical outcomes

Procedural and clinical outcomes are described in Table 2. The occurrence of valve malpositioning was higher in the AKI group compared with TIRFI and stable renal function groups (8.4% vs. 2.0% vs. 2.8%, respectively; P = 0.004). Also, major or life-threatening bleeding was higher in AKI group (20.2% vs. 6.7% vs. 6.3%, respectively; P < 0.001) as well as major vascular complication (10.5% vs. 3.6% vs. 4.0%, respectively; P = 0.006).

[Figure omitted. See PDF.]

Table 2. Procedural, 30-day and 1-year outcomes.

https://doi.org/10.1371/journal.pone.0251066.t002

Impact of TIRFI and AKI on short-term outcomes

At 30 days, patients in AKI group had higher rates of all-cause mortality compared with TIRFI and stable renal function groups (13.0% vs. 2.0% vs. 1.2%, respectively; P < 0.001), and also had higher rates of cardiovascular death (10.6% vs. 1.5% vs. 0.6%, respectively; P < 0.001). There was no significant difference regarding all stroke/transient ischemic attack and myocardial infarction and there was no significant difference in outcomes between TIRFI and stable renal function groups.

Follow-up at 1 year and loss of follow-up

Of the 577 patients included in our study, 157 (27.2%) patients lost follow-up or did not complete 1 year of follow-up until the time for data collection for the Brazilian TAVR Registry. However, the median follow-up of the patients included in the present study was 385 [162–742] days. Data comparing the baseline characteristics of the patients with loss of follow-up and those with complete 1-year follow-up are shown as supplemental data (S1 Table).

Impact of TIRFI and AKI on long-term outcomes

At 1 year, AKI group remained with higher rates of all-cause mortality compared with TIRFI and stable renal function groups (29.3% vs. 15.4% vs. 9.5%, respectively; P < 0.001), and had higher rates of cardiovascular death (21.0% vs. 6.0% vs. 4.5%, respectively; P < 0.001). There was still no difference regarding stroke/transient ischemic attack and myocardial infarction and there was no significant difference in outcomes between TIRFI and stable renal function groups group. Kapplan-Meier curves for 1-year all-cause mortality are represented in Fig 2.

[Figure omitted. See PDF.]

Fig 2. Kaplan-Meier curves for 1-year all-cause mortality.

Comparison of TIRFI group vs. AKI group (A), TIRFI group vs. stable renal function group (B) and stable renal function group vs. AKI group (C) 1-Year all-cause mortality rates. Abbreviations: AKI indicates acute kidney injury; SRFG indicates stable renal function group; TIRFI indicates TAVR induced renal function improvement.

https://doi.org/10.1371/journal.pone.0251066.g002

Predictors of TIRFI and AKI

Multivariate analysis of TIRFI and AKI are shown in Tables 3 and 4, respectively. The absence of coronary artery disease was an independent predictor of TIRFI (OR: 0.69; 95% CI 0.48–0.98; P = 0.039) as well as lower baseline eGFR (OR: 0.98; 95% CI 0.97–1.00; P = 0.008). Otherwise, independent predictors of AKI were age (HR: 1.03; 95% CI, 1.00–1.05; P = 0.033), hypertension (HR: 1.69; 95% CI, 1.11–2.57; P = 0.014), non-transfemoral access sites (HR: 2.07; 95% CI, 1.06–4.07; P = 0.034) and higher baseline eGFR (HR: 1.01; 95% CI, 1.00–1.02; P = 0.053). The multivariable analysis of TIRFI and AKI including the procedure complications after TAVR in the model are shown in S2 and S3 Tables).

[Figure omitted. See PDF.]

Table 3. Predictors of TIRFI after TAVR procedure.

https://doi.org/10.1371/journal.pone.0251066.t003

[Figure omitted. See PDF.]

Table 4. Predictors of AKI after TAVR procedure.

https://doi.org/10.1371/journal.pone.0251066.t004

Predictors of 1-year all-cause mortality

Univariable and multivariable predictors of 1-year all-cause mortality are shown in Table 5. The presence of AKI was associated with an increase in 1-year all-cause mortality (HR: 3.42; 95% CI, 1.87–6.23; P < 0.001), as well as chronic obstructive pulmonary disease (HR: 1.72; 95% CI, 1.06–2.79; P = 0.028), baseline eGFR (HR 0.72; 95% CI, 0.61–0.86. P < 0.001) and stroke/transient ischemic attack (HR: 3.08; 95% CI, 1.74–5.44; P < 0.001).

[Figure omitted. See PDF.]

Table 5. Multivariable predictors of 1-year all-cause mortality.

https://doi.org/10.1371/journal.pone.0251066.t005

Discussion

The main findings of the present study can be summarized as: (1) CKD was extremely prevalent among our population, corresponding to 70% of the patients; (2) TIRFI was frequently found after TAVR; (3) predictors of TIRFI were the absence of coronary artery disease and lower eGFR at baseline; (4) patients with AKI after TAVR had higher all-cause mortality and cardiovascular death at 30 days and 1 year; (5) there was no differences comparing 30-day and 1-year outcomes between TIRFI and stable renal function groups.

Patients with severe AS often have multiple comorbidities, and impaired renal function is associated with poor outcomes with surgical aortic valve replacement [21] and TAVR procedure [10, 11, 22]. Beyond that, the high proportion of CKD among these patients, ranging from 52% to 72% in previous large studies [10, 11, 21] reflects the impact of these comorbidities. In our study, CKD was present in 577 (70%) of the patients from the Brazilian TAVR Registry, with an average age of 80 years and high-surgical risk according STS score.

An interesting point of our study is that TIRFI occurred similarly compared with those with AKI or stable renal function (34.1% vs. 35.2% vs. 30.7%, respectively), despite all the adverse procedural features, such as the use of contrast media, atherosclerotic particles renal embolization during catheter passage through the aorta and deployment of the valve prosthesis [23], and also the occurrence of low cardiac output during rapid ventricle pacing for balloon expandable prosthesis deployment or pre- or post-dilation of the aortic valve, which was associated with acute kidney injury and short- and long-term mortality if multiple (≥ 3 episodes) or prolonged rapid ventricular pacing duration (≥ 36 seconds) are performed [24].

Attempting to determine the predictors of TIRFI, we found that the absence of coronary artery disease and lower eGFR were independent predictors for renal function recovery after TAVR. Regarding to eGFR as a predictor of TIRFI, the lower the eGFR, the greater is the chance of improvement in renal function. It can suggest that improvement in renal function is primarily due to the hemodynamics effects after TAVR procedure to relief aortic stenosis, increasing the cardiac output and leading to a better renal perfusion, suggesting that a mechanism of type 2 cardiorenal syndrome may be involved [25]. In the present analysis, there was no difference between the 3 groups related to contrast volume, use of diuretics and other variables that may contribute to deterioration of renal function. Importantly, the baseline eGFR was slightly lower among patients in the TIRFI group when compared with the AKI group, corroborating for the hypothesis that low cardiac output may be the main mechanism of impaired renal function at baseline in these population and explain why the presence of lower eGFR was found as an independent predictor of TIRFI. Also, patients without coronary artery disease may have less peripheral artery disease incidence and lower rates of atherosclerotic emboli during the TAVR procedure, and that may partially explain the association with TIRFI.

The presence of hypertension and higher age were associated with AKI, and the endothelial dysfunction added to the occurrence of low cardiac output during the procedure could be more harmful for this population. Furthermore, the use of non-transfemoral access sites was associated with AKI after TAVR, as well as AKI group had also more procedure complications such as valve malpositioning, major or life-threatening bleeding and major vascular complication. Also, the higher eGFR at baseline, the greater is the chance of developing AKI after TAVR. This finding was probably related simply to the percentage variation of eGFR in a high-risk population with multiple comorbidities, since the results of the statistical analysis were borderline.

According to previous studies, AKI was associated with poor outcomes, including higher 1-year all-cause and cardiovascular mortality rates [9, 16, 26]. However, our study did not show association between TIRFI and lower 30-days and 1-year all-cause mortality or other outcomes when compared with stable renal function group. Our results also sustain the findings from the subanalysis of Partner 1 which included a similar population and showed no reduction in mortality rates and other outcomes in the TIRFI group [9].

A recent single-center prospective study showed that patients who had TIRFI after TAVR may also have better 30-day and 2-year outcomes, independently of the baseline kidney function [16]. The reason for discordance of our findings with this recent study could be in part because our study population surgical risk was slightly higher using the STS score, which may justify an increase in mortality even in the stable renal function and TIRFI groups.

Limitations

This is a prospective observational multicenter study using the Brazilian TAVR Registry and there are several inherent limitations. First, data was self-reported by each center and on-site source document verification was randomly performed in only 20% of cases. Registries studies usually do not perform source document verification, and therefore, we consider that 20% of random verification is a representative sample to validity of the data. Besides that, there is no data about measure of urine output, pre- and post-hydration strategies and proteinuria levels that might be important for AKI definition. Since there is no definition of TIRFI, we arbitrary used variation in eGFR between baseline and at discharge after TAVR of 10% for both TIRFI and AKI criteria. As most of the patients had high-surgical risk using STS score, we could not extrapolate our results for intermediate- and low-surgical risk patients. Also, despite coronary angiography are usually performed before admission for TAVR, as a routine, for evaluation of concomitant coronary artery disease in Brazilian centers which included patients in the Brazilian TAVR Registry, information on how many patients had coronary angiography and percutaneous coronary intervention during the admission for TAVR was not available. Finally, we had around 27% loss of follow-up at 1 year. However, the median follow-up of the patients included in the present study was 385 [162–742] days, and therefore, we have chosen to assess the outcomes at 1 year.

Conclusion

In our study, TIRFI was frequently found in patients with prior impaired renal function and promoted lower mortality when compared with patients with AKI. The absence of coronary artery disease and lower eGFR at baseline were independent predictors of TIRFI.

Supporting information

S1 Table. Baseline and procedural characteristics of patients with loss of follow-up versus patients with complete 1-year follow-up.

https://doi.org/10.1371/journal.pone.0251066.s001

(DOCX)

S2 Table. Predictors of TIRFI after TAVR procedure (including outcomes).

https://doi.org/10.1371/journal.pone.0251066.s002

(DOCX)

S3 Table. Predictors of AKI after TAVR procedure (including outcomes).

https://doi.org/10.1371/journal.pone.0251066.s003

(DOCX)

S1 File.

https://doi.org/10.1371/journal.pone.0251066.s004

(XLSX)

Acknowledgments

The authors acknowledge the expert work of Rogério R. Prado for the statistical support.

Citation: Lemes da Silva MV, Nunes Filho ACB, Rosa VEE, Caixeta A, Lemos Neto PA, Ribeiro HB, et al. (2021) Improvement of renal function after transcatheter aortic valve replacement in patients with chronic kidney disease. PLoS ONE 16(5): e0251066. https://doi.org/10.1371/journal.pone.0251066

References

1. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. New England Journal of Medicine 2010;363(17):1597–607.

2. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. New England Journal of Medicine 2011;364(23):2187–98. pmid:21639811

3. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. New England Journal of Medicine 2014;370(19):1790–98.

4. Popma JJ, Adams DH, Reardon MJ, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. Journal of the American College of Cardiology 2014;63(19):1972–81. pmid:24657695

5. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. New England Journal of Medicine 2016;374(17):1609–20.

6. Thourani VH, Kodali S, Makkar RR, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. The Lancet 2016;387(10034):2218–25. pmid:27053442

7. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. New England Journal of Medicine 2019;380(18):1695–705.

8. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. New England Journal of Medicine 2019;380(18):1706–15. pmid:30883053

9. Beohar N, Doshi D, Thourani V, et al. Association of transcatheter aortic valve replacement with 30-day renal function and 1-year outcomes among patients presenting with compromised baseline renal function: experience from the PARTNER 1 Trial and Registry. JAMA cardiology 2017;2(7):742–49. pmid:28467527

10. Ferro CJ, Chue CD, de Belder MA, et al. Impact of renal function on survival after transcatheter aortic valve implantation (TAVI): an analysis of the UK TAVI registry. Heart 2015;101(7):546–52. pmid:25582121

11. Oguri A, Yamamoto M, Mouillet G, et al. Impact of chronic kidney disease on the outcomes of transcatheter aortic valve implantation: results from the FRANCE 2 registry. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 2015;10(9):e1–9. pmid:25599700

12. Chen C, Zhao Z-G, Liao Y-B, et al. Impact of renal dysfunction on mid-term outcome after transcatheter aortic valve implantation: a systematic review and meta-analysis. PLoS One 2015;10(3):e0119817. pmid:25793780

13. Nguyen TC, Babaliaros VC, Razavi SA, et al. Impact of varying degrees of renal dysfunction on transcatheter and surgical aortic valve replacement. The Journal of thoracic and cardiovascular surgery 2013;146(6):1399–407. pmid:24075566

14. Dumonteil N, Van Der Boon RM, Tchetche D, et al. Impact of preoperative chronic kidney disease on short-and long-term outcomes after transcatheter aortic valve implantation: a Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC-Plus) initiative substudy. American heart journal 2013;165(5):752–60. pmid:23622912

15. Faillace BL, Ribeiro HB, Campos CM, et al. Potential of transcatheter aortic valve replacement to improve post-procedure renal function. Cardiovascular Revascularization Medicine 2017;18(7):507–11. pmid:29054156

16. Nijenhuis VJ, Peper J, Vorselaars VM, et al. Prognostic Value of Improved Kidney Function After Transcatheter Aortic Valve Implantation for Aortic Stenosis. The American journal of cardiology 2018;121(10):1239–45. pmid:29525062

17. Nunes Filho AC, Katz M, Campos CM, et al. Impact of acute kidney injury on short-and long-term outcomes after transcatheter aortic valve implantation. Revista Española de Cardiología (English Edition) 2019;72(1):21–29. pmid:29358043

18. de Brito FS Jr., Carvalho LA, Sarmento-Leite R, et al. Outcomes and predictors of mortality after transcatheter aortic valve implantation: results of the Brazilian registry. Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions 2015;85(5):E153–62. pmid:25510532

19. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clinical Practice 2012;120(4):c179–c84. pmid:22890468

20. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. European heart journal 2012;33(19):2403–18. pmid:23026477

21. Thourani VH, Keeling WB, Sarin EL, et al. Impact of preoperative renal dysfunction on long-term survival for patients undergoing aortic valve replacement. The Annals of thoracic surgery 2011;91(6):1798–807. pmid:21536247

22. Conrotto F, Salizzoni S, Andreis A, et al. Transcatheter aortic valve implantation in patients with advanced chronic kidney disease. The American journal of cardiology 2017;119(9):1438–42. pmid:28325569

23. Scherner M, Wahlers T. Acute kidney injury after transcatheter aortic valve implantation. Journal of thoracic disease 2015;7(9):1527. pmid:26543598

24. Fefer P, Bogdan A, Grossman Y, et al. Impact of rapid ventricular pacing on outcome after transcatheter aortic valve replacement. Journal of the American Heart Association 2018;7(14):e009038. pmid:29987119

25. Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. European heart journal 2010;31(6):703–11. pmid:20037146

26. Gargiulo G, Sannino A, Capodanno D, et al. Impact of postoperative acute kidney injury on clinical outcomes after transcatheter aortic valve implantation: A meta-analysis of 5,971 patients. Catheterization and Cardiovascular Interventions 2015;86(3):518–27. pmid:25641565